Page 11 - Reflections_dyslipidaemia_newsletter4_2023
P. 11

REFLECTIONS
                                                                                                                   Dyslipidaemia
     Dyslipidaemia Global Newsletter #4 2023





       Condition/intervention                                            Effect on Lp(a) levels                    Dyslipidaemia
       Lifestyle
       Replacement of dietary saturated fat with carbohydrate or unsaturated fat           ↑ ~10–15%
       Low carbohydrate diet high in saturated fat                                           ↓ ~15%
       Fasting                                                                                None
       Physical activity                                                                  None/minimal
       Hormones and related conditions
       Hyperthyroidism                                                     ↓; ↑ 20–25% with thyrostatic treatment or radioactive
                                                                                          iodine therapy

       Hypothyroidism                                                            ↑; ↓ 5–20% with replacement therapy
       Growth hormones                                                                   ↑ 2x with therapy
       Endogenous sex hormones                                                            None/minimal
       Pregnancy                                                                              ↑ 2x
       Menopause                                                                          None/minimal
       Postmenopausal HRT                                                                    ↓ ~25%
       Surgical or biochemical castration in males                                           ↑ Small
       Ovariectomy, oestrogen receptor antagonist                                            ↑ Small
       Chronic kidney disease
       Nephrotic syndrome                                                               ↑ 3–5 x (vs. control)
       Peritoneal dialysis patients                                                      ↑ 2 x (vs. control)
       Hemodialysis treatment and CKD                                              ↑ in large apo(a) isoform carriers
       Kidney transplantation                                                         ~Normalization of levels
       Hepatic impairment                                                              ↓, depending on cause
       Liver transplantation                                               Changes of apo(a) isoform to that of the donor, with
                                                                                 corresponding changes in Lp(a) levels

       Inflammation and related conditions
       Severe, life-threatening acute-phase conditions (sepsis, severe burns)                  ↓
       Several inflammatory conditions                                                         ↑
       Tocilizumab (interleukin-6 inhibitor)                                               ↓~30–40%
       Protease inhibitors or antiretroviral therapy                                           ↑
       Statins                                                               ↑ slightly Lp(a) (but reports are heterogeneous)
       Air pollution (fine particulate, PM 2.5)                                              ↑Slight
     ↑, increase; ↓, decrease.


     There is strong support for a causal and continuous association between Lp(a) concentration and ASCVD, AVS, and CV, and all-
     cause mortality in men and women and across ethnic groups. Elevated Lp(a) has been identified as a risk factor for patients even
     with very low levels of LDL-C, but is not a risk factor for venous thrombosis. On the other hand, very low levels of Lp(a) may be
     associated with increased risk of T2DM. The mechanism underlying this association is not explained by established risk factors or
     known diabetes variants and it is unknown if the risk is causal.










          TABLE OF CONTENTS
   6   7   8   9   10   11   12   13   14